#### FORM D

## **UNITED STATES**

SEC Mail SECURITIES AND EXCHANGE COMMISSION

Meil Processing Section

Washington, D.C. 20549

AUG 2 8 2008

FORM D

NOTICE OF SALE OF SECURITIES

Washington, DC PURSUANT TO REGULATION D **SECTION 4(6), AND/OR** 106

UNIFORM LIMITED OFFERING EXEMPTION

	<u> </u>
	PROVAL
OMB Number:	3235-0076
Expires:	August 31, 2008
Estimated averag	

SEC USE ONLY

DATE RECEIVED

Prefix

Serial

Name of Offering ( check if this is an Sale of Common Stock	amendment and name has changed, and indic		
Filing under (Check box(es) that apply):  Type of Filing:   New Filing	Rule 504 Rule 505 Rule 506 Amendment	Section 4(6)	ULOE 
	A. BASIC IDENTIFICATION DATA		
1. Enter the information requested about	it the issuer	to change )	
Name of Issuer (L) check if this is an a Novelos Therapeutics, Inc.	mendment and name has changed, and indicate	te change.)	ATTIM ATTELIEVA ATTAL DIVE COM ABULLALA BULLERA
	nber and Street, City, State, Zip Code)	Telephone Num 617-244-1616	
	(Number and Street, City, State, Zip Code)	Telephone Num	08059016
Brief Description of Business	ned to commercialize drugs for the treatmen	nt of cancer and hepati	tis PROCESSED
Type of Business Organization			σ <b>Λ</b> / 1
	limited partnership, already formed	other (please specify):	SEP 0 4 2008
☐ business trust ☐	limited partnership, to be formed		THOMSON REUTER
Actual or Estimated Date of Incorporation	0 0 0 0 -	Actual Estin	• •
Jurisdiction of Incorporation or Organizat	ion: (Enter two- letter U.S. Postal Service abbre CN for Canada; FN for other foreign jurisdi	eviation for State: iction)	DE

## **General Instructions**

# Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230,501 et sea, or 15 U.S.C. 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

## State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on the ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

## **ATTENTION**

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

<ul> <li>Enter the information requested for the following:</li> <li>Each promoter of the issuer, if the issuer has be</li> </ul>	een organized within the past five	years;			
<ul> <li>Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;</li> </ul>					
Each executive officer and director of corporate issuers; and	e issuers and of corporate genera	I managing partners	of partnership		
<ul> <li>Each general and managing partnership of partnership</li> </ul>	tnership issuers.				
Check Box(es) that Apply: Promoter Beneficial C			General and/or anaging Partner		
Full Name (Last name first, if individual) Hill, Stephen A.					
Business or Residence Address (Number and Street, City, Clo Novelos Therapeutics, Inc., One Gateway Center, Su	State, Zip Code) ite 504, Newton, MA 02458				
Check Box(es) that Apply:			General and/or anaging Partner		
Full Name (Last name first, if individual) Palmin, Harry S.		-			
Business or Residence Address (Number and Street, City,	State, Zip Code)				
c/o Novelos Therapeutics, Inc., One Gateway Center, Su					
Check Box(es) that Apply:	Owner		General and/or anaging Partner		
Full Name (Last name first, if individual) Fass, Sim, Ph.D.					
Business or Residence Address (Number and Street, City, c/o Novelos Therapeutics, Inc., One Gateway Center, Su	State, Zip Code) rite 504, Newton, MA 02458				
Check Box(es) that Apply:	Owner		General and/or anaging Partner		
Full Name (Last name first, if individual)  McWilliams, David B.					
Business or Residence Address (Number and Street, City, c/o Novelos Therapeutics, Inc., One Gateway Center, St	State, Zip Code) tite 504, Newton, MA 02458				
Check Box(es) that Apply:	Owner		General and/or anaging Partner		
Full Name (Last name first, if individual) Schneider, Howard M.		<u> </u>			
Business or Residence Address (Number and Street, City, c/o Novelos Therapeutics, Inc., One Gateway Center, Su	State, Zip Code) site 504, Newton, MA 02458	<u> </u>			
Check Box(es) that Apply:	Owner		General and/or anaging Partner		
Full Name (Last name first, if individual) <b>Doyle, Michael J</b> .					
Business or Residence Address (Number and Street, City, c/o Novelos Therapeutics, Inc., One Gateway Center, Su	State, Zip Code) ui <b>te 504, Newton, MA 02458</b>				
Check Box(es) that Apply:	Owner		General and/or anaging Partner		
Full Name (Last name first, if individual)  Protano, Joanne M.					
Business or Residence Address (Number and Street, City, c/o Novelos Therapeutics, Inc., One Gateway Center, Su	State, Zip Code) aite 504, Newton, MA 02458				
Check Box(es) that Apply:	Owner		General and/or anaging Partner		
Full Name (Last name first, if individual)  Nyberg, Elias					
Business or Residence Address (Number and Street, City, c/o Novelos Therapeutics, Inc., One Gateway Center, St			<del>-</del>		

A. BASIC IDENTIFICATION DATA

		A. BASIC IDENTIFICA	TION DATA (continue	ed)		
and the state of the following:						
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner		Director	General and/or Managing Partner	
Full Name (Last name first, if indi Pazoles, Christopher J., Ph	vidual) .D.					
Business or Pesidence Address	(Number	and Street, City, State, Zi	p Code)			
c/o Novelos Therapeutics, I	nc., One Gate	way Center, Suite 504	, Newton, MA 02458			
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner		Director	☐ General and/or Managing Partner	
Full Name (Last name first, if ind Schuhwerk, Kristin C.	vidual)					
Business or Residence Address c/o Novelos Therapeutics,	(Number nc., One Gate	and Street, City, State, Zi way Center, Suite 504	p Code) , Newton, MA 02458			
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	☐ Executive Officer	☑ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if ind Manuso, James S., Ph.D.						
Business or Residence Address c/o Novelos Therapeutics,	(Number Inc., One Gate	and Street, City, State, Zi way Center, Suite 504	p Code) , Newton, MA 02458			
Check Box(es) that Apply:	Promoter	☑ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner	
Full Name (Last name first, if ind Xmark Opportunity Fund, L						
Business or Residence Address 90 Grove Street, Ridgefield		and Street, City, State, Z	p Code)			
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	☐ General and/or Managing Partner	
Full Name (Last name first, if ind Caduceus Capital Master F	und Limited	<u> </u>				
Business or Residence Address c/o OrbiMed Advisors, LLC	(Number , 767 Third Av	and Street, City, State, Zienue, 30 <sup>th</sup> Floor, New	ip Code) York, NY 10017			
Check Box(es) that Apply:	Promoter	Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner	
Full Name (Last name first, if ind Knoll Capital Fund II Maste						
Business or Residence Address c/o KOM Capital Manageme		and Street, City, State, Zivenue, Suite 3702, No.			-	
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner	
Full Name (Last name first, if ind Europa International, Inc.	ividual)					
Business or Residence Address c/o KOM Capital Manageme	(Number ent, 666 Fifth A	and Street, City, State, Z Avenue, Suite 3702, N	ip Code) ew York, NY 10103			
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner	
Full Name (Last name first, if ind Hunt-BioVentures, L.P.	ividual)					
Business or Residence Address 1900 N. Akard Street, Dalla		and Street, City, State, Z	ip Code)			

	<del> </del>	A. BASIC IDENTIFICA	TION DATA (continue	ed)	
4. Enter the information r	equested for the	following:			
Check Box(es) that Apply:	Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, if it Longview Fund, L.P.					
Business or Residence Addres 600 Montgomery Street, 4	s (Number 14 <sup>th</sup> Floor, San F	and Street, City, State, Zi rancisco, CA 94111	p Code)		
Check Box(es) that Apply:	Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, if i Longview Equity Fund, L					
Business or Residence Addres 600 Montgomery Street, 4	ss (Number 14 <sup>th</sup> Floor, San F	rand Street, City, State, Zi rancisco, CA 94111	p Code)		
Check Box(es) that Apply:	☐ Promoter	☑ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (Last name first, if i Longview International E	ndividual) <b>quity Fund, L</b> .P.				
Business or Residence Addres	ss (Number 14 <sup>th</sup> Floor, San F	r and Street, City, State, Zi rancisco, CA 94111	p Code)		

4 of 7

	B. INFORMATION ABOUT OFFERING		
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?	Yes □	No ⊠
	Answer also in Appendix, Column 2, if filing under ULOE.		
2.	What is the minimum investment that will be accepted from any individual?	None	
3.	Does the offering permit joint ownership of a single unit?	Yes ⊠	No □
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchases in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.		
Fu	Il Name (Last name first, if individual)		
Bu	siness or Residence Address (Number and Street, City, State, Zip Code)		
Na	me of Associated Broker or Dealer		
(CI [AL] (IL) [MT [RI]	☐ [IN] ☐ [IA] ☐ [KS] ☐ [KY] ☐ [LA] ☐ [ME] ☐ [MD] ☐ [MA] ☐ [MI] ☐ [MN] ☐ [M] ☐ [M] ☐ [M] ☐ [ND] ☐ [OH] ☐ [OK] ☐ [O ☐ [SC] ☐ [SD] ☐ [TN] ☐ [TX] ☐ [UT] ☐ [VT] ☐ [VA] ☐ [WA] ☐ [WY] ☐ [WI] ☐ [W] ☐	Š] □ R] □	ates [ID]  [MO]  [PA]  [PR]  [PR]
Bu —	siness or Residence Address (Number and Street, City, State, Zip Code)		
Na	me of Associated Broker or Dealer		
(CI [AL] [IL] [MT [RI]		S)	ates [ID]  [MO]  [PA]  [PR]  [PR]  [PR]
			<del></del>
Bu	siness or Residence Address (Number and Street, City, State, Zip Code)		
	me of Associated Broker or Dealer		
(C [AL] [IL]	[AK]   [AZ]   [AR]   [CA]   [CO]   [CT]   [DE]   [DC]   [FI]   [GA]   [H     [IN]   [IA]   [KS]   [KY]   [LA]   [ME]   [MD]   [MA]   [MI]   [MN]   [MN]   [M]     [NE]   [INV]   [INH]   [INJ]   [INM]   [INY]   [INC]   [IND]   [OH]   [OK]   [O     [SC]   [SD]   [TN]   [TX]   [UT]   [VT]   [VA]   [WA]   [WV]   [WI]   [MI]	s) 🔲	ates [ID]  [MO]  [PA]  [PR]  [PR]  [PR]  [PR]  [PR]  [PR]  [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

#### C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box ☐ and indicate in the columns below the amounts of the securities offered for exchange and already exchanged. **Amount Already** Aggregate Offering Price Sold Type of Security \$0 Debt ..... <u>\$0</u> \$3,000,000 \$3,000,000 Equity ..... ☐ Preferred □ Common \$0 Convertible Securities (including warrants) \$0 <u>\$0</u> Partnership Interests ..... <u>\$0</u> \$0 \$0 Other (Specify \_ \$3,000,000 Total ..... \$3,000,000 Answer also in Appendix, Column 3, if filing under ULOE. Enter the number of accredited and non-accredited investors who have purchased securities in Aggregate this offering and the aggregate dollar amounts of their purchases. For offerings under Rule Number of Dollar Amount 504, indicate the number of persons who have purchased securities and the aggregate dollar **Investors** of Purchases amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero." <u>2</u> \$3,000,000 Accredited Investors ..... 0 \$0 Non-accredited Investors ..... Total (for filing under Rule 504 only) ..... Answer also in Appendix, Column 4, if filing under ULOE. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offenings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1. Type of **Dollar Amount** Security Sold Type of offering Rule 505..... Regulation A..... Rule 504..... Total. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.

6 of 7

Total ...... 🖾 \$25,000

\$2,975,000

Enter the difference between the aggregate offering price given in response to Part C-Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer."

C. OFFERING PRIC	E, NUMBER OF INVESTORS, EXPENSES AND	JUSE OF FI	COCLEDO	
used for each of the purposes shown. I estimate and check the box to the left o equal the adjusted gross proceeds to the	ed gross proceeds to the issuer used or propose f the amount for any purpose is not known, furni f the estimate. The total of the payments listed r ne issuer set forth in response to Part C- Questi	nust		
above.		D	ayments to Officers, irectors, & Affiliates	Payments To Others
Salaries and fees		🗆 \$		<b>\$</b>
				□\$
	tallation of machinery and equipment			□\$
	ildings and facilities			<b></b>
Acquisition of other business (inclu	iding the value of securities involved in this offer the assets or securities of another issuer pursual	ng nt		□\$
	no assets of document of a linear participation of the second of the sec			<del></del>
Repayment of indebtedness		🗆 \$		<b>\$</b> _
Working capital		🗆 \$_		<b>■</b> \$2,975,000
Other (specify):		🗆 \$		<b></b> \$
Column Totals		🗆 \$		□ \$
Total Payments Listed (column tot	als added)		<b>□</b> \$ <u>2,975</u>	000
	D. FEDERAL SIGNATURE			
following signature constitutes an undertaki	e signed by the undersigned duly authorized per ng by the issuer to furnish to the U.S. Securities I by the issuer to any non-accredited investor pu	and Exchang	je Commissio	on, upon written
Issuer (Print or Type)	Signardre /	Date		
Novelos Therapeutics, Inc.	Hillell Paraus	August 26,	2008	
Name of Signer (Print or Type)  Joanne M. Protano	Title of Signer (Print or Type) Chief Financial Officer			
Joanne M. Protano	_ ·			
Intentional misstatements or omissi	ATTENTION ons of fact constitute federal criminal violation	ons. (See 18	U.S.C. 1001.	

